Lina Marenco-Hillembrand1, Olindi Wijesekera2, Paola Suarez-Meade1, David Mampre3, Christina Jackson4, Jennifer Peterson5, Daniel Trifiletti5, Julie Hammack6, Kyle Ortiz7, Elizabeth Lesser8, Matthew Spiegel8, Calder Prevatt1, Maria Hawayek7, Alfredo Quinones-Hinojosa1, Kaisorn L Chaichana9. 1. Department of Neurological Surgery, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL, 32224, USA. 2. Department of Neurological Surgery, Case Western University, Cleveland, OH, USA. 3. School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 4. Department of Neurological Surgery, Johns Hopkins University, Baltimore, MD, USA. 5. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA. 6. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. 7. School of Medicine, University of Puerto Rico, San Juan, PR, USA. 8. Division of Biomedical Statistics and Bioinformatics, Mayo Clinic, Jacksonville, FL, USA. 9. Department of Neurological Surgery, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL, 32224, USA. Chaichana.Kaisorn@mayo.edu.
Abstract
INTRODUCTION: Despite aggressive treatment with chemoradiotherapy and maximum surgical resection, survival in patients with glioblastoma (GBM) remains poor. Ongoing efforts are aiming to prolong the lifespan of these patients; however, disparities exist in reported survival values with lack of clear evidence that objectively examines GBM survival trends. We aim to describe the current status and advances in the survival of patients with GBM, by analyzing median overall survival through time and between treatment modalities. METHODS: A systematic review was conducted according to PRISMA guidelines to identify articles of newly diagnosed glioblastoma from 1978 to 2018. Full-text glioblastoma papers with human subjects, ≥ 18 years old, and n ≥ 25, were included for evaluation. RESULTS: The central tendency of median overall survival (MOS) was 13.5 months (2.3-29.6) and cumulative 5-year survival was 5.8% (0.01%-29.1%), with a significant difference in survival between studies that predate versus postdate the implementation of temozolomide and radiation, [12.5 (2.3-28) vs 15.6 (3.8-29.6) months, P < 0.001]. In clinical trials, bevacizumab [18.2 (10.6-23.0) months], tumor treating fields (TTF) [20.7 (20.5-20.9) months], and vaccines [19.2 (15.3-26.0) months] reported the highest central measure of median survival. CONCLUSION: Coadministration with radiotherapy and temozolomide provided a statistically significant increase in survival for patients suffering from glioblastoma. However, the natural history for GBM remains poor. Therapies including TTF pooled values of MOS and provide means of prolonging the survival of GBM patients.
INTRODUCTION: Despite aggressive treatment with chemoradiotherapy and maximum surgical resection, survival in patients with glioblastoma (GBM) remains poor. Ongoing efforts are aiming to prolong the lifespan of these patients; however, disparities exist in reported survival values with lack of clear evidence that objectively examines GBM survival trends. We aim to describe the current status and advances in the survival of patients with GBM, by analyzing median overall survival through time and between treatment modalities. METHODS: A systematic review was conducted according to PRISMA guidelines to identify articles of newly diagnosed glioblastoma from 1978 to 2018. Full-text glioblastoma papers with human subjects, ≥ 18 years old, and n ≥ 25, were included for evaluation. RESULTS: The central tendency of median overall survival (MOS) was 13.5 months (2.3-29.6) and cumulative 5-year survival was 5.8% (0.01%-29.1%), with a significant difference in survival between studies that predate versus postdate the implementation of temozolomide and radiation, [12.5 (2.3-28) vs 15.6 (3.8-29.6) months, P < 0.001]. In clinical trials, bevacizumab [18.2 (10.6-23.0) months], tumor treating fields (TTF) [20.7 (20.5-20.9) months], and vaccines [19.2 (15.3-26.0) months] reported the highest central measure of median survival. CONCLUSION: Coadministration with radiotherapy and temozolomide provided a statistically significant increase in survival for patients suffering from glioblastoma. However, the natural history for GBM remains poor. Therapies including TTF pooled values of MOS and provide means of prolonging the survival of GBMpatients.
Authors: Mario Teo; Sean Martin; Kevin Owusu-Agyemang; Stefan Nowicki; Brian Clark; Mairi Mackinnon; Willie Stewart; James Paul; Jerome St George Journal: Br J Neurosurg Date: 2013-10-10 Impact factor: 1.596
Authors: James Schuster; Rose K Lai; Lawrence D Recht; David A Reardon; Nina A Paleologos; Morris D Groves; Maciej M Mrugala; Randy Jensen; Joachim M Baehring; Andrew Sloan; Gary E Archer; Darell D Bigner; Scott Cruickshank; Jennifer A Green; Tibor Keler; Thomas A Davis; Amy B Heimberger; John H Sampson Journal: Neuro Oncol Date: 2015-01-13 Impact factor: 12.300
Authors: Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Neuro Oncol Date: 2017-11-06 Impact factor: 12.300
Authors: Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin Journal: Eur J Cancer Date: 2012-05-18 Impact factor: 9.162
Authors: Kaisorn L Chaichana; Tomas Garzon-Muvdi; Scott Parker; Jon D Weingart; Alessandro Olivi; Richard Bennett; Henry Brem; Alfredo Quiñones-Hinojosa Journal: Ann Surg Oncol Date: 2010-08-10 Impact factor: 5.344
Authors: Roy Rampling; Sharon Peoples; Paul J Mulholland; Allan James; Omar Al-Salihi; Christopher J Twelves; Catherine McBain; Sarah Jefferies; Alan Jackson; Willie Stewart; Juha Lindner; Sarah Kutscher; Norbert Hilf; Lesley McGuigan; Jane Peters; Karen Hill; Oliver Schoor; Harpreet Singh-Jasuja; Sarah E Halford; James W A Ritchie Journal: Clin Cancer Res Date: 2016-05-25 Impact factor: 12.531